Table 4 Dosages of most common antifungal drugs in paediatric IPA
From: Management of pulmonary aspergillosis in children: a systematic review
Drug | Dosage by age group | Adverse events | |||
|---|---|---|---|---|---|
Newborns | 1–24 months | 2–12 years | 13–18 years | ||
Voriconazole e.v (mg/Kg/die) | Not approved | Not approved | 14 (in 2 doses) | 8 (in 2 doses) | Visual disturbances Hepatotoxicity Hypersensitivity Skin rash |
Voriconazole per os (mg/die) | Not approved | Not approved | 400 (in 2 doses) | 400 (in 2 doses) | |
Conventional amphotericin e.v (mg/Kg/die) | 1–1,5 | 1–1,5 | 1–1,5 | 1–1,5 | Nephrotoxicity Electrolyte disturbances Hypersensitivity |
Amphotericin lipid formulation (mg/Kg/die) | 5 3–5 NA | 5 3–5 3–4 | 5 3–5 3–4 | 5 3–5 3–4 | Mild nephrotoxicity Electrolyte disturbances |
Caspofungin (mg/m2/die) | 25 | 50 (max 70); 70 per day 1 | 50 (max 70); 70 per day 1 | 50 (max 70); 70 per day 1 | Fever Hepatotoxicity Cutaneous rash Tachycardia Headache |
Posaconazole per os (mg/die) | NA | NA | NA | 800 (in 2 o 4 doses) | Hepatotoxicity Nausea and vomiting Headache |
Itraconazole per os (mg/Kg/die) | NA | NA | 5 (in 2 doses) | 5 (in 2 doses) | Abdominal pain Nausea Skin rash |